Abstract | OBJECTIVE: BACKGROUND: HS is still a common cause of death in severely injured patients and is characterized by impairment of organ perfusion, systemic inflammatory response, and multiple organ failure. There is no specific therapy that reduces organ injury/dysfunction. Artesunate exhibits pharmacological actions beyond its antimalarial activity, such as anticancer, antiviral, and anti-inflammatory effects. METHODS: Rats were submitted to HS. Mean arterial pressure was reduced to 30 mm Hg for 90 minutes, followed by resuscitation. Rats were randomly treated with artesunate (2.4 or 4.8 mg/kg i.v.) or vehicle upon resuscitation. Four hours later, parameters of organ injury and dysfunction were assessed. RESULTS: CONCLUSIONS:
|
Authors | Regina Sordi, Kiran K Nandra, Fausto Chiazza, Florence L Johnson, Claudia P Cabrera, Hew D Torrance, Noriaki Yamada, Nimesh S A Patel, Michael R Barnes, Karim Brohi, Massimo Collino, Christoph Thiemermann |
Journal | Annals of surgery
(Ann Surg)
Vol. 265
Issue 2
Pg. 408-417
(02 2017)
ISSN: 1528-1140 [Electronic] United States |
PMID | 28059970
(Publication Type: Journal Article)
|
Chemical References |
- Artemisinins
- Biomarkers
- Protective Agents
- Artesunate
|
Topics |
- Animals
- Artemisinins
(therapeutic use)
- Artesunate
- Biomarkers
(metabolism)
- Combined Modality Therapy
- Male
- Multiple Organ Failure
(etiology, metabolism, prevention & control)
- Protective Agents
(therapeutic use)
- Random Allocation
- Rats
- Rats, Wistar
- Resuscitation
(adverse effects)
- Shock, Hemorrhagic
(metabolism, therapy)
- Treatment Outcome
|